Clinical insights into pharmacogenetics and schizo...[J Clin Psychiatry. 2008] - PubMed Result

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: J Clin Psychiatry. 2008 Jun;69(6):1006-13. Links

Clinical insights into pharmacogenetics and schizophrenia, part 2.

Kane JM, Perlis RH, Malhotra AK.

Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA.

PMID: 18683996 [PubMed - indexed for MEDLINE]

Related articles

Review[Tolcapone in the management of Parkinson's disease]
Zh Nevrol Psikhiatr Im S S Korsakova. 2007; 107(6):71-8.

[Zh Nevrol Psikhiatr Im S S Korsakova. 2007]
Update on "open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder".
J Clin Psychopharmacol. 2000 Apr; 20(2):285.

[J Clin Psychopharmacol. 2000]
ReviewTreatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.
CNS Drugs. 2007; 21(7):535-57.

[CNS Drugs. 2007]
ReviewCatechol-O-methyltransferase inhibitors: new options for Parkinson's disease.
S D J Med. 1999 Aug; 52(8):295-7.

[S D J Med. 1999]
ReviewCOMT inhibition and safety.
Funct Neurol. 2001; 16(4 Suppl):135-40.

[Funct Neurol. 2001]
» See reviews... | » See all...

Patient Drug Information

Tolcapone (Tasmar® )
Tolcapone is used in combination with levodopa and carbidopa to treat the signs and symptoms of Parkinson's disease.
Source: AHFS Consumer Medication Information

Recent Activity

Clear Turn Off Turn On

Clinical insights into pharmacogenetics and schizophrenia, part 2.Clinical insights into pharmacogenetics and schizophrenia, part 2.

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show